Australia markets closed

Mereo BioPharma Group plc (MREO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.2500+0.2600 (+6.52%)
At close: 04:00PM EDT
4.2510 +0.00 (+0.02%)
After hours: 07:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 596.16M
Enterprise value 553.52M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)57.68
Price/book (mrq)13.92
Enterprise value/revenue 55.35
Enterprise value/EBITDA -1.21

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 3214.81%
S&P500 52-week change 323.76%
52-week high 34.4100
52-week low 31.0700
50-day moving average 33.1335
200-day moving average 32.6399

Share statistics

Avg vol (3-month) 31.04M
Avg vol (10-day) 31.74M
Shares outstanding 5140.27M
Implied shares outstanding 6140.24M
Float 8439.92M
% held by insiders 10.54%
% held by institutions 160.03%
Shares short (15 May 2024) 42.21M
Short ratio (15 May 2024) 42.72
Short % of float (15 May 2024) 41.90%
Short % of shares outstanding (15 May 2024) 41.58%
Shares short (prior month 15 Apr 2024) 42.77M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -263.41%
Operating margin (ttm)-256.48%

Management effectiveness

Return on assets (ttm)-20.59%
Return on equity (ttm)-55.90%

Income statement

Revenue (ttm)10M
Revenue per share (ttm)0.07
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -25.04M
Net income avi to common (ttm)-26.34M
Diluted EPS (ttm)-0.1500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)48.66M
Total cash per share (mrq)0.07
Total debt (mrq)6.02M
Total debt/equity (mrq)14.05%
Current ratio (mrq)4.86
Book value per share (mrq)0.31

Cash flow statement

Operating cash flow (ttm)-19.88M
Levered free cash flow (ttm)-12.14M